Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study - Zhou, C; Wu, Y L; Chen, G (Lancet Oncol, 2011)
, et al.